The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases

Kevin J. Whitehead, Aubrey C. Chan, Sutip Navankasattusas, Wonshill Koh, Nyall London, Jing Ling, Anne H. Mayo, Stavros G. Drakos, Douglas A. Marchuk, George E. Davis, Dean Y. Li

Research output: Contribution to journalArticle

Abstract

Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug.

Original languageEnglish (US)
Pages (from-to)177-184
Number of pages8
JournalNature medicine
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Central Nervous System Cavernous Hemangioma
rho GTP-Binding Proteins
Blood Vessels
Simvastatin
GTP Phosphohydrolases
Endothelial cells
Blood vessels
Neurology
Pharmaceutical Preparations
Genes
Chemical activation
Cell Communication
Central Nervous System
Endothelial Cells
Genotype
Pharmacology
Phenotype
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Whitehead, K. J., Chan, A. C., Navankasattusas, S., Koh, W., London, N., Ling, J., ... Li, D. Y. (2009). The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nature medicine, 15(2), 177-184. https://doi.org/10.1038/nm.1911

The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. / Whitehead, Kevin J.; Chan, Aubrey C.; Navankasattusas, Sutip; Koh, Wonshill; London, Nyall; Ling, Jing; Mayo, Anne H.; Drakos, Stavros G.; Marchuk, Douglas A.; Davis, George E.; Li, Dean Y.

In: Nature medicine, Vol. 15, No. 2, 01.02.2009, p. 177-184.

Research output: Contribution to journalArticle

Whitehead, KJ, Chan, AC, Navankasattusas, S, Koh, W, London, N, Ling, J, Mayo, AH, Drakos, SG, Marchuk, DA, Davis, GE & Li, DY 2009, 'The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases', Nature medicine, vol. 15, no. 2, pp. 177-184. https://doi.org/10.1038/nm.1911
Whitehead, Kevin J. ; Chan, Aubrey C. ; Navankasattusas, Sutip ; Koh, Wonshill ; London, Nyall ; Ling, Jing ; Mayo, Anne H. ; Drakos, Stavros G. ; Marchuk, Douglas A. ; Davis, George E. ; Li, Dean Y. / The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. In: Nature medicine. 2009 ; Vol. 15, No. 2. pp. 177-184.
@article{47f72b27700a4653862d29d1122a4b65,
title = "The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases",
abstract = "Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug.",
author = "Whitehead, {Kevin J.} and Chan, {Aubrey C.} and Sutip Navankasattusas and Wonshill Koh and Nyall London and Jing Ling and Mayo, {Anne H.} and Drakos, {Stavros G.} and Marchuk, {Douglas A.} and Davis, {George E.} and Li, {Dean Y.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1038/nm.1911",
language = "English (US)",
volume = "15",
pages = "177--184",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases

AU - Whitehead, Kevin J.

AU - Chan, Aubrey C.

AU - Navankasattusas, Sutip

AU - Koh, Wonshill

AU - London, Nyall

AU - Ling, Jing

AU - Mayo, Anne H.

AU - Drakos, Stavros G.

AU - Marchuk, Douglas A.

AU - Davis, George E.

AU - Li, Dean Y.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug.

AB - Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug.

UR - http://www.scopus.com/inward/record.url?scp=59649084619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649084619&partnerID=8YFLogxK

U2 - 10.1038/nm.1911

DO - 10.1038/nm.1911

M3 - Article

C2 - 19151728

AN - SCOPUS:59649084619

VL - 15

SP - 177

EP - 184

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -